Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6951 to 7000 of 8236 results

  1. Liquid-based cytology for cervical screening (TA5)

    This guidance has been replaced by NICE technology appraisal guidance 69.

    Technology appraisal guidance
    Published
    26 June 2000

  2. Management of aggression, agitation and behavioural disturbances in dementia: valproate preparations (ESUOM41)

    This evidence summary has been updated and replaced by NICE guideline NG97.

    Evidence summary
    Published
    10 March 2015

  3. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA760)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA1042

    Technology appraisal guidance
    Published
    12 January 2022

  4. Rezum for treating benign prostatic hyperplasia (MIB158)

    This advice has been updated and replaced by NICE medical technologies guidance 49. 

    Medtech innovation briefing
    Published
    24 August 2018

  5. Trabecular stent bypass microsurgery for open angle glaucoma (IPG396)

    This guidance has been updated and replaced by NICE interventional procedure guidance 575.

    Interventional procedures guidance
    Published
    25 May 2011

  6. Off-pump coronary artery bypass (OPCAB) (IPG35)

    This guidance has been updated and replaced by NICE interventional procedure guidance 377.

    Interventional procedures guidance
    Published
    10 January 2004

  7. Hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus: telavancin (ESNM44)

    This evidence summary has been withdrawn because the product is no longer available in the UK.

    Evidence summary
    Published
    15 July 2014

  8. Falls in older people: assessing risk and prevention (CG161)

    This guideline has been updated and replaced by NICE guideline NG249.

    Clinical guideline
    Published
    12 June 2013

  9. Hormone-sensitive metastatic prostate cancer: docetaxel (ESUOM50)

    This evidence summary has been updated and replaced by NICE guideline NG131.

    Evidence summary
    Published
    5 January 2016

  10. Balloon disimpaction of the baby's head at emergency caesarean during the second stage of labour (IPG744)

    This guidance has been updated and replaced by NICE interventional procedures guidance 800.  

    Interventional procedures guidance
    Published
    16 November 2022

  11. Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA823)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1071.

    Technology appraisal guidance
    Published
    28 September 2022

  12. Lung cancer: diagnosis and management (CG121)

    This guidance has been updated and replaced by NICE guideline NG122.

    Clinical guideline
    Published
    21 April 2011

  13. Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (TA558)

    This guidance has been updated and replaced by NICE technology appraisal guidance 684.

    Technology appraisal guidance
    Published
    23 January 2019

  14. SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal) (TA834)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1045.

    Technology appraisal guidance
    Published
    12 October 2022

  15. Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (TA963)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1064

    Technology appraisal guidance
    Published
    3 April 2024

  16. TheraSphere for treating operable and inoperable hepatocellular carcinoma (MIB62)

    This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.

    Medtech innovation briefing
    Published
    30 March 2016

  17. EndoPredict gene expression profiling assay for assessing risk of breast cancer recurrence (MIB44)

    This advice has been updated and replaced by NICE diagnostics guidance 34.

    Medtech innovation briefing
    Published
    10 November 2015

  18. Non-cystic fibrosis bronchiectasis: long-term azithromycin (ESUOM38)

    This evidence summary has been updated and replaced by NICE guideline NG117.

    Evidence summary
    Published
    25 November 2014

  19. Cystic fibrosis: long-term azithromycin (ESUOM37)

    This evidence summary has been updated and replaced by NICE guideline NG78.

    Evidence summary
    Published
    25 November 2014

  20. Systemic lupus erythematosus: oral mycophenolate (ESUOM36)

    This evidence summary has been withdrawn following the MHRA pregnancy-prevention advice issued for women and men taking mycophenolate.

    Evidence summary
    Published
    18 November 2014

  21. Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal) (TA594)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1059.

    Technology appraisal guidance
    Published
    14 August 2019

  22. Mepilex Border dressings for preventing pressure ulcers (MIB124)

    This advice has been updated and replaced by NICE medical technologies guidance 40.

    Medtech innovation briefing
    Published
    6 October 2017

  23. Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation (TA578)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA798.

    Technology appraisal guidance
    Published
    1 May 2019

  24. SEM Scanner for pressure ulcer prevention (MIB182)

    This advice has been updated and replaced by NICE medical technologies guidance 51.

    Medtech innovation briefing
    Published
    8 May 2019

  25. Induction of labour in late intrauterine fetal death: vaginal misoprostol (after oral mifepristone) (ESUOM11)

    This evidence summary has been updated and replaced by NICE guideline NG207.

    Evidence summary
    Published
    30 April 2013

  26. Dapagliflozin for treating chronic kidney disease (TA775)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1075.

    Technology appraisal guidance
    Published
    9 March 2022

  27. Psychosis and schizophrenia: management (CG82)

    This guidance has been updated and replaced by NICE guideline CG178. This guideline updates and replaces NICE guideline CG1.

    Clinical guideline
    Published
    25 March 2009

  28. Insertion of a balloon device to disimpact an engaged fetal head before an emergency caesarean section (IPG515)

    This guidance has been updated and replaced by NICE interventional procedures guidance 800.

    Interventional procedures guidance
    Published
    27 March 2015

  29. SIR-Spheres for treating inoperable hepatocellular carcinoma (MIB63)

    This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.

    Medtech innovation briefing
    Published
    30 March 2016

  30. The clinical effectiveness and cost effectiveness of newer atypical antipsychotic drugs for schizophrenia (TA43)

    This guidance has been updated and replaced by NICE guideline CG82.

    Technology appraisal guidance
    Published
    26 June 2002

  31. Pneumonia (hospital-acquired): antimicrobial prescribing (NG139)

    This guideline has been updated and replaced by NICE's guideline on pneumonia: diagnosis and management (NG250).

    Antimicrobial prescribing guideline
    Published
    16 September 2019

  32. Pneumonia (community-acquired): antimicrobial prescribing (NG138)

    This guideline has been updated and replaced by NICE's guideline on pneumonia in adults: diagnosis and management (NG250).

    Antimicrobial prescribing guideline
    Published
    16 September 2019

  33. Pneumonia in adults: diagnosis and management (CG191)

    This guideline has been updated and replaced by NICE's guideline on pneumonia: diagnosis and management (NG250).

    Clinical guideline
    Last updated
    31 October 2023

  34. Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA611)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA1007.

    Technology appraisal guidance
    Published
    13 November 2019

  35. The clinical effectiveness and cost effectiveness of routine anti-D prophylaxis for RhD-negative women in pregnancy (TA41)

    This guidance has been updated and replaced by NICE technology appraisal guidance 156. 

    Technology appraisal guidance
    Published
    27 May 2002

  36. Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal) (TA564)

    This guidance has been updated and replaced by NICE technology appraisal guidance 898.

    Technology appraisal guidance
    Published
    27 February 2019

  37. Ruxolitinib for treating polycythaemia vera (terminated appraisal) (TA356)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA921.

    Technology appraisal guidance
    Published
    23 September 2015

  38. MI – secondary prevention: Secondary prevention in primary and secondary care for patients following a myocardial infarction (CG48)

    This guidance has been updated and replaced by NICE guideline CG172.

    Clinical guideline
    Published
    23 May 2007

  39. Adalimumab, etanercept and infliximab for ankylosing spondylitis (TA143)

    This guidance has been updated and replaced by NICE technology appraisal guidance 383.

    Technology appraisal guidance
    Published
    28 May 2008

  40. Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia (TA142)

    This guidance has been replaced by NICE technology appraisal guidance 323.

    Technology appraisal guidance
    Published
    28 May 2008

  41. Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (TA985)

    This guidance has been withdrawn because the simple discount patient access scheme for QuiremSpheres has been withdrawn.

    Technology appraisal guidance
    Published
    3 July 2024

  42. Suspected sepsis: recognition, diagnosis and early management (NG51)

    This guideline has been updated and replaced by NICE's guidelines on suspected sepsis in people aged 16 or over (NG253), suspected sepsis in under 16s (NG254) and suspected sepsis in pregnant or recently pregnant people (NG255).

    NICE guideline
    Last updated
    19 March 2024

  43. DMD Care UK's guideline on cardiac care of children with dystrophinopathy and females carrying DMD-gene variations: NICE review (NG251)

    We have moved NG251 to become a 'NICE Review'. This is to better reflect what the purpose of this product is and to help you find relevant content more quickly. The review itself has not changed. See NICE review 1 on DMD Care UK’s guideline on cardiac care of children with dystrophinopathy and females carrying DMD-gene variations.

    NICE guideline
    Published
    5 September 2025

  44. UrgoStart for chronic wounds (MIB82)

    This advice has been updated and replaced by NICE medical technologies guidance 42.

    Medtech innovation briefing
    Published
    5 October 2016

  45. VitalPAC for assessing vital signs of patients in hospital (MIB79)

    This advice has been updated and replaced by NICE medtech innovation briefing 205.

    Medtech innovation briefing
    Published
    14 September 2016

  46. Ultroid 2.0 for internal haemorrhoids (MIB75)

    This medtech innovation briefing is temporarily unavailable, please contact mibs@nice.org.uk for further information.

    Medtech innovation briefing
    Published
    26 July 2016

  47. Lutonix drug-coated balloon for peripheral arterial disease (MIB72)

    NICE withdrew this medtech innovation briefing in October 2019 after the MHRA withdrew support for this type of technology being used in intermittent claudication for arterial disease.

    Medtech innovation briefing
    Published
    26 July 2016

  48. Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)

    Discontinued Reference number: GID-TA10337

    Technology appraisal guidance
    Discontinued

  49. Atezolizumab for untreated advanced renal cell carcinoma [ID1365]

    Discontinued Reference number: GID-TA10338

    Technology appraisal guidance
    Discontinued

  50. Avelumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID1146]

    Discontinued Reference number: GID-TA10341

    Technology appraisal guidance
    Discontinued